MDT

100.66

-0.05%↓

133.89

-1.33%↓

VEEV

217.29

-0.15%↓

HQY

82.83

-0.01%↓

NEOG

10.35

+1.07%↑

MDT

100.66

-0.05%↓

133.89

-1.33%↓

VEEV

217.29

-0.15%↓

HQY

82.83

-0.01%↓

NEOG

10.35

+1.07%↑

MDT

100.66

-0.05%↓

133.89

-1.33%↓

VEEV

217.29

-0.15%↓

HQY

82.83

-0.01%↓

NEOG

10.35

+1.07%↑

MDT

100.66

-0.05%↓

133.89

-1.33%↓

VEEV

217.29

-0.15%↓

HQY

82.83

-0.01%↓

NEOG

10.35

+1.07%↑

MDT

100.66

-0.05%↓

133.89

-1.33%↓

VEEV

217.29

-0.15%↓

HQY

82.83

-0.01%↓

NEOG

10.35

+1.07%↑

Strona główna・Stock List・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Open

SectorHealthcare

223.58 -5.09

Buy Sell

Overview

Share price change

24h

Current

Min

223.34

Max

238.52

Key metrics
By Trading Economics
Income	-22M -61M
Sales	56M 214M
Profit margin	-28.549
Employees	1,017
EBITDA	-56M -53M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+14.67% upside

Dividends
By Dow Jones
Next Earnings	11 lut 2026

Market Stats
By TradingEconomics
Market Cap	2.4B 14B
Previous open	228.67
Previous close	223.58

News Sentiment

By Acuity

50%

148 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

157.66 / 167.29 Support & Resistance

Ascendis Pharma A-S ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 sty 2026, 23:07 UTC

Earnings

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

27 sty 2026, 21:27 UTC

Earnings

Texas Instruments 4Q Sales Rise, Profit Falls

27 sty 2026, 23:55 UTC

Market Talk

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

27 sty 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 sty 2026, 23:47 UTC

Market Talk

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

27 sty 2026, 23:39 UTC

Market Talk

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

27 sty 2026, 23:20 UTC

Earnings

SK Innovation: Asset-Impairment Losses Weighed on Earnings

27 sty 2026, 23:20 UTC

Earnings

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

27 sty 2026, 23:19 UTC

Earnings

SK Innovation Posts Net Loss for Second Consecutive Year

27 sty 2026, 23:19 UTC

Earnings

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

27 sty 2026, 23:18 UTC

Earnings

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

27 sty 2026, 23:18 UTC

Earnings

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

27 sty 2026, 23:11 UTC

Market Talk

Global Equities Roundup: Market Talk

27 sty 2026, 23:11 UTC

Market Talk

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

27 sty 2026, 23:07 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

27 sty 2026, 22:17 UTC

Market Talk

U.S. Dollar Slips Following Trump Comments -- Market Talk

27 sty 2026, 22:06 UTC

Earnings

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

27 sty 2026, 21:51 UTC

Earnings

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

27 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27 sty 2026, 21:43 UTC

Earnings

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

27 sty 2026, 21:41 UTC

Earnings

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

27 sty 2026, 21:38 UTC

Earnings

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

27 sty 2026, 21:32 UTC

Earnings

Ampol: Modest Profit From F&I International in 2025

27 sty 2026, 21:32 UTC

Earnings

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

27 sty 2026, 21:31 UTC

Earnings

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

27 sty 2026, 21:31 UTC

Earnings

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

27 sty 2026, 21:30 UTC

Earnings

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

27 sty 2026, 21:29 UTC

Earnings

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

27 sty 2026, 21:29 UTC

Earnings

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

27 sty 2026, 21:28 UTC

Earnings

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Peer Comparison

Price change

Ascendis Pharma A-S ADR Forecast

Price Target

By TipRanks

14.67% upside

12 Months Forecast

Average 269.91 USD 14.67%

High 330 USD

Low 240 USD

Based on 12 Wall Street analysts offering 12 month price targets forAscendis Pharma A-S ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Ascendis Pharma A-S ADR - Dist in the past 3 months.

Technical Score

By Trading Central

157.66 / 167.29Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

148 / 352 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.